210 related articles for article (PubMed ID: 15563241)
1. Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E.
Drugs R D; 2004; 5(6):355-8. PubMed ID: 15563241
[TBL] [Abstract][Full Text] [Related]
2. Safinamide (Newron Pharmaceuticals).
Chazot PL
Curr Opin Investig Drugs; 2001 Jun; 2(6):809-13. PubMed ID: 11572661
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
Fabbri M; Rosa MM; Abreu D; Ferreira JJ
Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
[TBL] [Abstract][Full Text] [Related]
4. Safinamide for the treatment of Parkinson's disease.
Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
[TBL] [Abstract][Full Text] [Related]
5. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Chazot PL
Curr Opin Investig Drugs; 2007 Jul; 8(7):570-9. PubMed ID: 17659477
[TBL] [Abstract][Full Text] [Related]
6. Safinamide: first global approval.
Deeks ED
Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
[TBL] [Abstract][Full Text] [Related]
8. Safinamide in the treatment of Parkinson's disease.
Schapira AH
Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
[TBL] [Abstract][Full Text] [Related]
10. Safinamide: a new hope for Parkinson's disease?
Teixeira FG; Gago MF; Marques P; Moreira PS; Magalhães R; Sousa N; Salgado AJ
Drug Discov Today; 2018 Mar; 23(3):736-744. PubMed ID: 29339106
[TBL] [Abstract][Full Text] [Related]
11. Safinamide for symptoms of Parkinson's disease.
Müller T
Drugs Today (Barc); 2015 Nov; 51(11):653-9. PubMed ID: 26744740
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
[TBL] [Abstract][Full Text] [Related]
13. Safinamide (Xadago) for Parkinson's disease.
Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847
[No Abstract] [Full Text] [Related]
14. Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies.
Wasan H; Singh D; Kh R
Brain Res Bull; 2021 Mar; 168():165-177. PubMed ID: 33387637
[TBL] [Abstract][Full Text] [Related]
15. Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
Müller T
Expert Rev Neurother; 2013 Sep; 13(9):969-77. PubMed ID: 24053341
[TBL] [Abstract][Full Text] [Related]
16. Safinamide: A Review in Parkinson's Disease.
Blair HA; Dhillon S
CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
Stocchi F; Torti M
Drug Des Devel Ther; 2016; 10():609-18. PubMed ID: 26917951
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
[TBL] [Abstract][Full Text] [Related]
19. Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures.
Maj R; Fariello RG; Pevarello P; Varasi M; McArthur RA; Salvati P
Epilepsia; 1999 Nov; 40(11):1523-8. PubMed ID: 10565578
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
Schapira AH; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R;
Eur J Neurol; 2013 Feb; 20(2):271-80. PubMed ID: 22967035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
